ストックスクリーナーアプリを入手
6.4648
4.29%
0.2748
前日終値:
$6.19
開ける：
$6.28
24時間の取引高:
300.91K
Relative Volume:
0.39
時価総額：
$354.62M
収益：
$124.00K
当期純損益:
$-49.99M
株価収益率:
-3.8253
EPS:
-1.69
ネットキャッシュフロー:
$-31.03M
1週間 パフォーマンス:
+18.01%
1か月 パフォーマンス:
+34.77%
6か月 パフォーマンス:
+29.89%
1年 パフォーマンス:
+7.23%
1日の値動き範囲:
$6.16
$6.50
1週間の範囲:
$5.405
$6.64
52週間の値動き範囲:
$3.785
$14.60
Candel Therapeutics Inc Stock (CADL) Company Profile
CADL を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
CADL
Candel Therapeutics Inc
|
6.46 | 339.80M | 124.00K | -49.99M | -31.03M | -1.69 |
|
VRTX
Vertex Pharmaceuticals Inc
|
407.81 | 104.55B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
472.68 | 60.36B | 2.46B | -319.09M | -52.09M | -2.4669 |
|
REGN
Regeneron Pharmaceuticals Inc
|
552.20 | 59.84B | 14.21B | 4.46B | 3.56B | 39.69 |
|
ARGX
Argen X Se Adr
|
809.14 | 49.07B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ONC
Beone Medicines Ltd Adr
|
331.45 | 35.16B | 4.56B | -176.77M | 225.30M | -1.7177 |
Candel Therapeutics Inc Stock (CADL) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-09-03 | ダウングレード | BofA Securities | Buy → Neutral |
| 2025-06-30 | 再開されました | H.C. Wainwright | Buy |
| 2025-02-20 | 開始されました | Citigroup | Buy |
| 2025-02-19 | 開始されました | Canaccord Genuity | Buy |
| 2025-02-07 | 開始されました | BofA Securities | Buy |
| 2022-12-02 | 開始されました | H.C. Wainwright | Buy |
| 2021-11-19 | 開始されました | BMO Capital Markets | Outperform |
| 2021-08-23 | 開始されました | Credit Suisse | Outperform |
| 2021-08-23 | 開始されました | Jefferies | Buy |
| 2021-08-23 | 開始されました | UBS | Buy |
すべてを表示
Candel Therapeutics Inc (CADL) 最新ニュース
Candel Therapeutics Has A Protracted, But Real, Timeline To Approval Now - Seeking Alpha
Can Candel Therapeutics Inc. stock sustain revenue growthEarnings Risk Report & Technical Confirmation Alerts - newser.com
Will Candel Therapeutics Inc. stock deliver strong dividend growth2025 Market Trends & Low Risk High Win Rate Stock Picks - newser.com
What MACD signals say about Candel Therapeutics Inc.Market Risk Report & Real-Time Volume Analysis - newser.com
Analyzing drawdowns of Candel Therapeutics Inc. with statistical tools2025 Price Momentum & Scalable Portfolio Growth Ideas - newser.com
How to interpret RSI for Candel Therapeutics Inc. stockWeekly Loss Report & Daily Momentum Trading Reports - newser.com
Weiss Ratings Reiterates "Sell (D-)" Rating for Candel Therapeutics (NASDAQ:CADL) - MarketBeat
Is Candel Therapeutics Inc a good long term investmentProtective Put Strategies & Outstanding Wealth Building - earlytimes.in
Visual trend scoring systems applied to Candel Therapeutics Inc.July 2025 Price Swings & High Win Rate Trade Tips - newser.com
Price momentum metrics for Candel Therapeutics Inc. explainedWeekly Trading Summary & Community Verified Trade Signals - newser.com
Candel Therapeutics stock rating reiterated at Buy by H.C. Wainwright - Investing.com
How resilient is Candel Therapeutics Inc. stock in market downturns2025 Market Overview & Free Weekly Chart Analysis and Trade Guides - newser.com
Is Candel Therapeutics Inc. stock bottoming outQuarterly Trade Summary & Community Consensus Trade Signals - newser.com
Why Candel Therapeutics Inc. stock remains undervalued2025 Earnings Surprises & Reliable Entry Point Trade Alerts - newser.com
Candel Therapeutics to present insights from enLIGHTEN Discovery Platform at SITC 2025 meeting - Proactive financial news
Candel Therapeutics to Present at the SITC 2025 Annual Meeting - The Manila Times
Candel Therapeutics to Present New Insights on Immunotherapy at SITC 40th Annual Meeting - Quiver Quantitative
Positive Phase 3 CAN-2409 data — Candel Therapeutics presents prostate cancer & NSCLC at SITC Nov 2025 - Stock Titan
Is Candel Therapeutics Inc. stock a smart buy before Fed meetingMarket Growth Summary & Stock Portfolio Risk Control - newser.com
Using Ichimoku Cloud for Candel Therapeutics Inc. technicals2025 Buyback Activity & Precise Buy Zone Tips - newser.com
Candel Therapeutics’ CAN-2409 delivers durable benefit in positive phase 3 prostate cancer trial - Proactive financial news
Tanager Wealth Management LLP Purchases New Shares in Candel Therapeutics, Inc. $CADL - MarketBeat
H.C. Wainwright reiterates Buy rating on Candel Therapeutics stock at $23 price target - Investing.com Australia
Candel Therapeutics Inc. stock retracement – recovery analysisLayoff News & Daily Growth Stock Investment Tips - newser.com
H.C. Wainwright Maintains Candel Therapeutics(CADL.US) With Buy Rating, Maintains Target Price $23 - 富途牛牛
HC Wainwright & Co. Reiterates Candel Therapeutics (CADL) Buy Recommendation - Nasdaq
CADL Analyst Rating: HC Wainwright & Co. Maintains 'Buy' Rating | CADL Stock News - GuruFocus
CADL Analyst Rating: HC Wainwright & Co. Maintains 'Buy' Rating - GuruFocus
HC Wainwright Reiterates "Buy" Rating for Candel Therapeutics (NASDAQ:CADL) - MarketBeat
Candel Therapeutics Presents Phase 3 Clinical Trial of CAN-2409 in Localized Prostate Cancer at ASTRO 2025 - GlobeNewswire
Candel Therapeutics presents phase 3 clinical trial of CAN-2409 - MarketScreener
Candel trial shows promise for gene therapy in prostate cancer - Proactive financial news
Candel Therapeutics Reports Positive Phase 3 Trial Results for CAN-2409 in Intermediate-to-High-Risk Localized Prostate Cancer at ASTRO 2025 - Quiver Quantitative
30% Better Survival: Candel's Breakthrough Prostate Cancer Drug Shows Success Across All Radiation Types - Stock Titan
Candel Therapeutics Inc (CADL) 財務データ
収益
当期純利益
現金流量
EPS
Candel Therapeutics Inc (CADL) インサイダートレーディング
| インサイダートレーディング | 関係 | 日付 | 取引 | コスト | #株式 | 値 ($) | #株式総数 |
|---|---|---|---|---|---|---|---|
| Nichols William Garrett | Chief Medical Officer |
Jul 28 '25 |
Sale |
6.98 |
937 |
6,540 |
52,493 |
| Nichols William Garrett | Chief Medical Officer |
Jun 30 '25 |
Option Exercise |
1.29 |
781 |
1,007 |
53,274 |
| Nichols William Garrett | Chief Medical Officer |
Jun 30 '25 |
Sale |
5.04 |
781 |
3,936 |
52,493 |
1.10%
大文字化:
|
ボリューム (24 時間):